Drug intelligence / Profile preview

QR-333

Development stage: Phase 2
Lead developer: Quigley Pharma
Modality: Small Molecules
Administration: Topical

Overview

**QR-333** was an investigational topical fixed-dose cream developed by Quigley Pharma for symptomatic diabetic peripheral neuropathy. The formulation combined quercetin, ascorbyl palmitate, and vitamin D3. Quercetin was intended to inhibit aldose reductase and, together with the antioxidant components, reduce oxidative stress and inflammation implicated in diabetic peripheral nerve injury. QR-333 was evaluated in completed Phase II studies but was not approved or marketed.

Other names: QR 333QR333QR-333

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on QR-333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR-333.

Explore the full profile